Use of thermobalancing therapy in ageing male with benign prostatic hyperplasia with a focus on etiology and pathophysiology

References

• Lin KH, Lin YW, Wen YC, Lee LM. Efficacy and safety of orally disintegrating tamsulosin tablets in Taiwanese patients with benign prostatic hyperplasia. Aging Male 2012;15:246–52
   PubMed Web of Science ®Google Scholar
• Wada N, Hashizume K, Matsumoto S, Kakizaki H. Dutasteride improves bone mineral density in male patients with lower urinary tract symptoms and prostatic enlargement: a preliminary study. Aging Male 2016;19:12–14
   PubMed Web of Science ®Google Scholar
• Fourcade RO, Lacoin F, Rouprêt М, et al. Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia. World J Urol 2012;30:419–26
   PubMed Web of Science ®Google Scholar
• Yassin AA, El-Sakka AI, Saad F, Gooren LJ. Lower urinary-tract symptoms and testosterone in elderly men. World J Urol 2008;26:359–64
   PubMed Web of Science ®Google Scholar
• Yassin A, Nettleship JE, Talib R, et al. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male 2016;19:64–9
   PubMed Web of Science ®Google Scholar
• Meuleman EJ, Legros JJ, Bouloux PM, et al. Study 43203 Investigators., Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male 2015;18:157–63
   PubMed Web of Science ®Google Scholar
• Efesoy O, Apa D, Tek M, Çayan S. The effect of testosterone treatment on prostate histology and apoptosis in men with late-onset hypogonadism. Aging Male 2016;19:79–84
   PubMed Web of Science ®Google Scholar
• Bhasin S, Singh AB, Mac RP, et al. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 2003;24:299–311
   PubMed Web of Science ®Google Scholar
• Wu CP, Gu FL. The prostate in eunuchs. Prog Clin Biol Res 1991;370:249–55
   PubMedGoogle Scholar
• Schatteman PH, Hoekx L, Wyndaele JJ. Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur Urol 2000;37:404–12
   PubMed Web of Science ®Google Scholar
• Bostanci Y, Kazzazi A, Momtahen S, et al. Correlation between benign prostatic hyperplasia and inflammation. Curr Opin Urol 2013;23:5–10
   PubMed Web of Science ®Google Scholar
• DiBello JR, Ioannou C, Rees J, et al. Prevalence of metabolic syndrome and its components among men with and without clinical benign prostatic hyperplasia: a large, cross-sectional, UK epidemiological study. BJU Int 2016;117:801–8
   PubMed Web of Science ®Google Scholar
• Demir O, Akgul K, Akar Z, et al. Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome. The Aging Male 2009;12:29–34
   PubMed Web of Science ®Google Scholar
• Yang TK, Hsieh JT, Chen SC, et al. Metabolic syndrome associated with reduced lower urinary tract symptoms in middle-aged men receiving health checkup. Urology 2012;80:1093–7
   PubMed Web of Science ®Google Scholar
• Shimizu S, Tsounapi P, Shimizu T, et al. Lower urinary tract symptoms, benign prostatic hyperplasia/benign prostatic enlargement and erectile dysfunction: are these conditions related to vascular dysfunction? Int J Urol 2014;21:856–64
   PubMed Web of Science ®Google Scholar
• Saito M, Tsounapi P, Oikawa R, et al. Prostatic ischemia induces ventral prostatic hyperplasia in the SHR; possible mechanism of development of BPH. Sci Rep 2014;4:3822. doi: 10.1038/srep03822
   PubMed Web of Science ®Google Scholar
• Thurmond P, Yang JH, Azadzoi KM. LUTS in pelvic ischemia: a new concept in voiding dysfunction. Am J Physiol Renal Physiol 2016. doi: 10.1152/ajprenal.00333.2015
   PubMed Web of Science ®Google Scholar
• Cohen PG. Abdominal obesity and intra-abdominal pressure: a new paradigm for the pathogenesis of the hypogonadal-obesity-BPH-LUTS connection. Horm Mol Biol Clin Investig 2012;11:317–20
   PubMedGoogle Scholar
• Aghajanyan IG, Allen S. Positive response to thermobalancing therapy enabled by therapeutic device in men with non-malignant prostate diseases: BPH and chronic prostatitis. Diseases 2016;4:18
   Google Scholar
• Allen S, Aghajanyan I. Thermobalancing therapy can improve the quality of life of patients with urological diseases: chronic prostatitis, BPH and kidney stones. Kidney Urol 2016;Res 1:004
   Google Scholar
• Allen S, Adjani A. Therapeutic Device and Method, United States Patent and Trademark Office, 2016, 14 pages, Patent No: US 9,408,744 B2. Available from: https://www.google.com/patents/US9408744
   Google Scholar
• Allen S, Aghajanyan IG. Benign prostatic hyperplasia treatment with new physiotherapeutic device. Urol J 2015;12:2371–6
   PubMed Web of Science ®Google Scholar
• Salah Azab S, Elsheikh MG. The impact of the bladder wall thickness on the outcome of the medical treatment using alpha-blocker of BPH patients with LUTS. Aging Male 2015;18:89–92
   PubMed Web of Science ®Google Scholar
• Karakose A, Aydogdu O, Yusuf Ziya Atesci YZ. The relationship between bladder wall thickness and lower urinary tract symptoms: does bladder wall thickness change after alpha-blocker therapy with alfuzosin? Can Urol Assoc J 2014;8:E26–9
   Google Scholar
• Martin S, Vincent A, Taylor AW, et al. Lower urinary tract symptoms, depression, anxiety and systemic inflammatory factors in men: a population-based cohort study. PLoS One 2015;10:e0137903
   PubMed Web of Science ®Google Scholar
• Pinto JD, He HG, Chan SW, Wang W. Health-related quality of life and psychological well-being in men with benign prostatic hyperplasia: an integrative review. Jpn J Nurs Sci 2016;13:309–23
   PubMed Web of Science ®Google Scholar
• Wiygul J, Babayan RK. Watchful waiting in benign prostatic hyperplasia. Curr Opin Urol 2009;19:3–6
   PubMed Web of Science ®Google Scholar
• Füllhase C, Hakenberg O. New concepts for the treatment of male lower urinary tract symptoms. Curr Opin Urol 2015;25:19–26
   PubMed Web of Science ®Google Scholar
• Jack AS. Inflammation in the pathophysiology of benign prostatic hypertrophy. Eur Urol Suppl 2015;14:1455–8
   Web of Science ®Google Scholar
• De Nunzio C, Cindolo L, Gacci M, et al. Metabolic syndrome and lower urinary tract symptoms in patients with benign prostatic enlargement: a possible link to storage symptoms. Urology 2014;84:1181–7
   PubMed Web of Science ®Google Scholar
• Kim JH, Doo SW, Yun JH, et al. Lower likelihood of having moderate-to-severe lower urinary tract symptoms in middle-aged healthy korean men with metabolic syndrome. Urology 2014;84:665–9
   PubMed Web of Science ®Google Scholar
• Yeh HC, Liu CC, Lee YC, et al. Associations of the lower urinary tract symptoms with the lifestyle, prostate volume, and metabolic syndrome in the elderly males. Aging Male 2012;15:166–72
   PubMed Web of Science ®Google Scholar
• Allen S, Aghajanyan I. Thermobalancing conservative treatment for moderate-to-low-degree lower urinary tract symptoms (LUTS) secondary to prostate enlargement. Cogent Med 2016;3:1195067. doi: http://dx.doi.org/10.1080/2331205X.2016.1195067
   Google Scholar
• Allen S, Aghajanyan I. Effect of thermobalancing therapy on chronic prostatitis and chronic pelvic pain syndrome. J Clin Urol 2016;1–8. doi: 10.1177/2051415816671036
   Google Scholar
• Gandaglia G, Briganti A, Gontero P, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int 2013;112:432–41
   PubMed Web of Science ®Google Scholar
• Solonin YG, Katsyuba EA. Thermoregulation and blood circulation in adults during short-term exposure to extreme temperatures. Fiziol Cheloveka 2003;29:67–74
   PubMedGoogle Scholar
• Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res. Ther 2013;15:S3
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med 2013;10:e1001388
   PubMed Web of Science ®Google Scholar
• Corona G, Vignozzi L, Rastrelli G, et al. Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. Int J Endocrinol 2014;2014:329456
   PubMed Web of Science ®Google Scholar
• Abrams P, Chapple C, Khoury S, et al. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol 2009;181:1779–87
   PubMed Web of Science ®Google Scholar
• Russo GI, Cimino S, Morgia G. Benign prostatic hyperplasia and metabolic syndrome: the expanding evidences of a new disease of aging male. Aging Male 2015;18:133–4
   PubMed Web of Science ®Google Scholar
• Pearson R, Williams PM. Common questions about the diagnosis and management of benign prostatic hyperplasia. Am Fam Physician 2014;90:769–74
   PubMed Web of Science ®Google Scholar